The Addictive Diagnostic Value of Apparent Diffusion Coefficients to PI-RADS 3-5 of Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer

What this Trial Is About

Researchers are evaluating how different Apparent Diffusion Coefficient (ADC) values from biparametric MRI (bpMRI) scans can improve the diagnosis of prostate cancer in patients with PI-RADS scores of 3 to 5. The study focuses on determining whether ADC values help better identify clinically significant prostate cancer (Gleason score 3+4 or higher, ISUP grade 2 or above) as well as any-grade prostate cancer (Gleason score 3+3 or higher, ISUP grade 1 or above). The study involves patients suspected of having prostate cancer who have undergone bpMRI and have PI-RADS scores between 3 and 5. Before prostate biopsy, researchers collect detailed information including age, BMI, PSA levels, prostate volume, ADC values, lesion size and location, among others. Prostate biopsy is then performed using systematic and possibly targeted methods, and pathological results serve as the gold standard for diagnosis. Diagnostic indicators such as ROC curves, sensitivity, specificity, and predictive values are calculated to compare how well different ADC values help diagnose prostate cancer. Participants provide clinical data and undergo standard bpMRI and biopsy procedures. Researchers analyze these results along with various diagnostic statistics and logistic regression to assess the value of ADC measurements in improving prostate cancer diagnosis. The primary outcome is to evaluate if ADC values enhance bpMRI's ability to detect clinically significant prostate cancer, with study completion expected around one month after enrollment. Secondary outcomes include assessing ADC's role in diagnosing any-grade prostate cancer and comparing diagnostic capacities based on PI-RADS scores combined with ADC cutoffs.

The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer